Expression Of The PBXIP1 Protein And Its Clinical Significance In The Pancreatic Cancer

Objective:By using the bioinformatics research methods,we found from the TCGA and the GTEx databases that PBXIP1 protein is highly expressed in various malignant tumor tissues.In this study,immunohistochemical staining was used to detect and verify the expression of PBXIP1 protein in pancreatic cancer.The follow-up data of postoperative patients with pancreatic cancer were collected and retrospectively analyzed to explore the relationgship between the expression of PBXIP1 protein and its clinicopathological features or survival.So this project aims to elucidate the clinical significance of PBXIP1 protein molecules in pancreatic cancer.Methods:1.This study retrospectively collected 60 specimens of pancreatic malignant tumors and 45 specimens of paracancerous pancreatic tissue,which were hospitalized in the biliary and pancreatic surgery of the People's Hospital of North Jiangsu from January 2015 to December 2018 and received surgery for pancreatic cancer.The normal pancreatic tissue specimens were obtained from the corresponding pancreatic cancer patients.We used immunohistochemical staining to detect the expression level of PBXIP1 protein in 60 pancreatic malignant tumors and 45 paracancerous pancreatic tissue samples.Chi-square test was used to detect Whether the PBXIP1 protein molecule is differentially expressed in pancreatic malignant tumors and normal pancreatic tissues;2.Collect the follow-up data of 60 patients with postoperative pancreatic cancer,we analyze the correlation between the expression level of PBXIP1 protein and the clinicopathological features of patients with pancreatic cancer according to the chi-square test results[clinicopathological features:Clinical stage of postoperative patients with pancreatic cancer(AJCC seventh edition)),T stage,N stage,M stage,degree of pathological differentiation of tumor,presence or absence of distant metastasis,presence or absence of vascular invasion,presence or absence of neurological invasion,etc.].3.By collecting the postoperative survival time of patients with pancreatic cancer,the factors affecting the prognosis of pancreatic cancer were screened by single factor analysis and verified in multivariate Cox regression analysis.Finally,we use the survival curve analysis by using analyze Kaplan-Meier analysis and The Log-rank test to explore whether PBXIP1 protein expression levels can affect the prognosis of pancreatic cancerResult:1.The results of immunohistochemical staining showed that the positive expression rate of PBXIP1 protein in pancreatic cancer tissue samples(38/60[63.3%])was higher than that in paracancerous pancreatic tissue sanples(19/45[42.2%]).Chi-square test analysis showed that PBXIP1 protein was differentially expressed in pancreatic cancer and normal pancreatic tissue(p=0.025,p<0.05).2.The positive expression of PBXIP1 protein is associated with T stage and vascular invasion of pancreatic tumors.The positive rate of PBXIP1 protein expression in T3-4 pancreatic cancer was generally higher than that in T1-2 pancreatic cancer(positive rates were 33/46[71.7%]and 5/14[35.7%],p=0.018<0.05).The positive rate of PBXIP1 protein expression was generally higher in vascular invasion(+)pancreatic cancer than in vascular invasion(-)pancreatic cancer(positive rates were 22/27[81.5%]and 16/33[48.5%],p=0.008<0.05).In this study,the expression level of PBXIP1 protein was not significantly correlated with clinical stage,pathological differentiation,lymph node metastasis,distant metastasis,and neurological invasion of cancer patients(p>0.05).3.Univariate analysis showed that TNM clinical stage and distant metastasis of pancreatic cancer patients had significant effects on postoperative prognosis of pancreatic cancer(p=0.02 and p<0.001,respectively).Multivariate Cox regression analysis showed that TNM clinical stage and distant metastasis of pancreatic cancer patients are independent risk factors for postoperative prognosis of pancreatic cancer.The prognosis of patients with pancreatic cancer TNM clinical stage ?-? pancreatic cancer was worse than that of stage ?-? pancreatic cancer patients,the difference was statistically significant(HR=0.20,p=0.005<0.05,HR 95%confidence interval[0.07-0.61]);the prognosis of patients with distant metastatic pancreatic cancer was worse than that of patients without distant metastasis.The difference was statistically significant(HR=15.39,p=0,006<0.05,HR 95%confidence interval[2.22-106.71]).Survival analysis of Kaplan-Meier and Log-rank test results showed that patients with high expression of PBXIP1 protein and received postoperative survival time of gemcitabine chemotherapy(mean survival time was[19.89 ± 1.79]months;median survival time was[18.10 ± 4.32]months)was survived significantly longer than postoperative cancer patients who did not receive chemotherapy(mean survival time was[12.46 ± 2.16]months;median survival time was[9.00 ± 3.24]months,p=0.037<0.05).Patients with low expression of PBXIP1 protein and received postoperative survival time of gemcitabine chemotherapy[12.02 ± 1.89]months;median survival time[12.30 ± 0.37]was not survived significantly differtnt from who without chemotherapy(mean survival time was[13.58±2.57]months;median survival time was[10.00 ± 4.38]months;p=0.756>0.05).Conclusion:1.The expression of PBXIP1 protein in pancreatic cancer tissues is higher than in paracancerous pancreatic tissues.2.PBXIPI protein positive expression is associated with tumor T stage and vascular invasion.PBXIP1 protein was not found to be associated with clinical stage,pathological differentiation.lymph node metastasis,distant metastasis,and neurological invasion.3.PBXIPI high expression of pancreatic cancer patients with postoperative gemcitabine chemotherapy is more effective,postoperative survival time increased.